Automated KYC for Pharmaceutical Companies

As with most regulated industries, pharmaceutical companies have their own specific challenges with supply chain and vendor due diligence, adverse media screening as well as customer onboarding and monitoring. Isolating the relevant data for complex entities is a common pain point for compliance teams at pharmaceutical companies who need to become more efficient with their time.

Arachnys have deep domain expertise in working with pharmaceutical companies to provide cloud-based solutions that align with their risk policy and reduce the burden of manual, laborious and inefficient processes.

Backed by unparalleled global data sources, we provide the tools to help you automate and accelerate manual effort in supply chain due diligence, customer and vendor onboarding, monitor adverse media and mitigate reputational risk.

Industry Problems


Pharmaceutical companies struggle with consistency and managerial oversight across due diligence processes, anti-money laundering and anti-bribery regulatory requirements.

Supply chain due diligence is one of the biggest pain points for compliance professionals at pharmaceuticals who need to conduct research across a multitude of countries and languages.

Regulators have warned that the pharmaceutical sector has been targeted by financial criminals seeking to execute frauds known as transaction laundering.

Arachnys Solutions


Automated AML & Investigations

Surface the content that matters, reduce duplication, manual effort and increase data re-use.

Automated KYC & Onboarding

Assemble everything you need to know about your customers and counterparties.

Automated Enhanced Due Diligence

Capture the information that matters and remove the noise of false positives.

We channel data into your ecosystem

We act as a single lens, accessing and enriching the best KYC & AML data from global sources, which connects your compliance ecosystem to the data you need to make more confident compliance decisions.

AML & KYC Data Sources


Better data: Unparalleled global source coverage enables you to run 100% of your external data gathering process through a single set of tools

Less noise: Capture only the relevant information that matters, removing the noise associated with manual search techniques

Localized: Surface content in 98 languages, supported in multiple scripts including Arabic, Chinese and Cyrillic, across 220 jurisdictions

Audit control: Prove your findings with consolidated reports which include heat maps, summaries of completed steps and supporting research

Reduce duplication: Curation tools for your external research processes with the ability to share and reuse data across your organisation

Integrate: Connect your organization's workflow applications directly to the external data they need to make better, faster decisions


Global data search: Continuously search across 23,000+ risk-relevant, open-source and premium providers in over 98 languages supported in multiple scripts (incl. Arabic, Chinese & Cyrillic) across 220 jurisdictions

Configurable investigative process management: Investigative policy configuration and execution, guides your analysts in accordance with AML alert clearing and KYC/CDD/EDD processes

Automated screening tools: Reduce investigative cycle time using automated content-acquisition methods, and reduce false positives using automated screening tools for risk categorisation and assessment

Risk identification, categorization and evidencing: Providing fast, accurate and consistent risk determinations with automatic audit trail for simple or complex investigations

Structured report creation: PDF report generation and export capabilities (with or without appendix, translated and non-translated)


Why a new pharmaceutical brand chose to improve their audit trail

A new pharmaceutical company needed the rapid implementation of a risk solution that they could trust. What was especially needed was a single platform to integrate structured and unstructured data sources for all due diligence research to be carried out in one environment. There were inconsistencies in investigations, and insufficient insights into compliance to correctly adhere to regulatory requirements.

Read the Case Study

The case for enhanced due diligence in the pharma sector – and how to achieve it

Pharmaceutical companies are among the most regulated businesses in the world, from drug safety bodies with exacting requirements to competition authorities determined to prevent market abuse. But while pharma businesses have developed sophisticated compliance functions to meet their obligations, it’s still possible to get caught out in less obvious areas.

Read the Blog Post

edd pharma

Get a Demo